Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Doxorubicin in Hepatocellular Carcinoma
NCT00083226Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2004
- Primary completion
- Feb 2011
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in hepatocellular carcinoma (HCC), sponsored by National Cancer Institute. Started Mar 2004; status: completed.
02
Drugs
bortezomib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00083226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083226.